肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

欧盟监管机构批准罗氏的组合疗法（Tecentriq、阿瓦斯汀和化疗药)用于一线治疗肺癌

2019-03-08 不详 MedSci原创

PD-L1单抗阿瓦斯汀化疗组合疗法
关注

罗氏周五宣布，欧盟委员会授权PD-L1单抗Tecentriq（atezolizumab）联合阿瓦斯汀（bevacizumab）和化疗药，用于转移性非鳞状非小细胞肺癌成人患者的一线治疗。该药物的获批是基于其三期IMpower150的试验数据。

罗氏周五宣布，欧盟委员会授权PD-L1单抗Tecentriq（atezolizumab）联合阿瓦斯汀（bevacizumab）和化疗药，用于转移性非鳞状非小细胞肺癌成人患者的一线治疗。该药物的获批是基于其三期IMpower150的试验数据。

罗氏全球产品开发负责人Sandra Horning表示："这项批准包括在靶向治疗失败后，为EGFR突变或ALK阳性的非小细胞肺癌患者提供一线治疗。"

IMpower150研究结果显示，与Avastin和化疗相比，Tecentriq联合阿瓦斯汀和化疗有助于人们活得更长，两组的中位总生存期分别为14.9个月和19.8个月。此外，与Avastin和化疗相比，Tecentriq与Avastin和化疗结合可将疾病恶化或死亡的风险降低41％。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2020-02-03 shock_melon

    #TEC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2019-10-03 yankaienglish

    #组合疗法#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2020-01-06 yhy100200

    #阿瓦斯汀#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2019-03-10 wwzzly

    #监管#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2019-03-10 lfyang

    #Tecentriq#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1652329, encodeId=7393165232961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Feb 03 18:53:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773065, encodeId=8dd31e7306543, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Oct 03 12:53:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929035, encodeId=15d2192903565, content=<a href='/topic/show?id=b94c9e908bf' target=_blank style='color:#2F92EE;'>#阿瓦斯汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97908, encryptionId=b94c9e908bf, topicName=阿瓦斯汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Jan 06 00:53:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371613, encodeId=d55513e1613fb, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581767, encodeId=f6221581e6790, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sun Mar 10 10:53:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2019-03-10 12498cb5m18暂无昵称

    #化疗药#

    0

相关资讯

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

阿斯利康（AZ）的Imfinzi被欧洲批准用于治疗局部晚期，不可切除的非小细胞肺癌（NSCLC）。